Nicotine Addiction Pipeline Insights Highlights Therapeutic Landscape and Ongoing Drug Development in 2017

Market Research HUB

Market Research HUB

Albany, US,  2017-Aug-16 — /EPR Network/ — Since many years, there are millions of people all over the world who are battling to combat nicotine addiction a fall out of cigarette smoking. Considering this fact, the tobacco addiction treatment field is progressing through innovations in medication development. Recently, a new study has been prepared by research experts which is titled as “Nicotine Addiction– Pipeline Insight, 2017”, and now added to the vast portfolio of Market Research Hub (MRH). The study provides comprehensive insights of the ongoing therapeutic research and development across Nicotine Addiction. Additionally, the report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products.

Request Free Sample Report:

Nicotine addiction is the second-leading cause of death worldwide. It has been one of the hardest for people to break. At present, Nicotine is the most addictive drug in the United States and over 400,000 people die from smoking related diseases. It has been analyzed that Nicotine is found naturally in tobacco, and its quantity has been increased in cigarettes and tobacco products over the years. Many people from professionals on down to the average citizen commonly refer to smoking and chewing tobacco as a habit.

In the first section, the report highlights precise overview of Nicotine addiction and its pipeline therapeutics. Nicotine addiction is a chronic brain disorder. Nicotine from cigarette smoke is rapidly absorbed into the lungs and then quickly passes into the brain. These are the most commonly associated diseases of nicotine usage, such as Heart disease, High blood pressure, Cancer; Trouble with the throat, esophagus, tongue, mouth; increased risk of breathing diseases, COPD, and Malnutrition. The research identifies that quitting smoking can be difficult and daunting due to the two sides of addiction that it presents. Every type of addiction has a chemical or physical side and a mental or psychological side.

Browse Full Report With TOC:

Moreover, a comparative pipeline therapeutics assessment of Nicotine Addiction by development stage, therapy type, route of administration and molecule type is also covered in the report. NRT is the most common medication used to assist in quit attempts. Other than nicotine replacement therapy like nicotine patches or gum, the drug varenicline is the only nicotinic agonist that is approved by the Food and Drug Administration and clinically available in the United States. Apart from that, products that are currently in clinical stage highlights drug name launched by companies are also mentioned. The drugs are profiled along with product description, its research & development and product development activities.

In the next part, the report also covers the dormant and discontinued pipeline projects related to the Nicotine Addiction. Through this crucial information, the readers can plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Nicotine Addiction therapeutics. The study also has a special feature on the inactive pipeline products in this area.

Enquire About this Report:


About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 866-997-4948 (US-Canada)


Read Industry News At:

Matched content

Editor’s pick

Express Press Release Distribution